GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pliant Therapeutics Inc (NAS:PLRX) » Definitions » PS Ratio

PLRX (Pliant Therapeutics) PS Ratio : (As of Dec. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pliant Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Pliant Therapeutics's share price is $14.20. Pliant Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00. Hence, Pliant Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Pliant Therapeutics's PS Ratio or its related term are showing as below:

PLRX' s PS Ratio Range Over the Past 10 Years
Min: 5.22   Med: 72.64   Max: 3817.5
Current: 511.25

During the past 6 years, Pliant Therapeutics's highest PS Ratio was 3817.50. The lowest was 5.22. And the median was 72.64.

PLRX's PS Ratio is ranked worse than
93.11% of 1016 companies
in the Biotechnology industry
Industry Median: 8.76 vs PLRX: 511.25

Pliant Therapeutics's Revenue per Sharefor the three months ended in Sep. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00.

Warning Sign:

Pliant Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Pliant Therapeutics was -100.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -76.00% per year.

During the past 6 years, Pliant Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -54.80% per year. The lowest was -76.00% per year. And the median was -65.40% per year.

Back to Basics: PS Ratio


Pliant Therapeutics PS Ratio Historical Data

The historical data trend for Pliant Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pliant Therapeutics PS Ratio Chart

Pliant Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - 11.60 63.98 83.68 670.74

Pliant Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 255.00 670.74 3,725.00 - -

Competitive Comparison of Pliant Therapeutics's PS Ratio

For the Biotechnology subindustry, Pliant Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pliant Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pliant Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Pliant Therapeutics's PS Ratio falls into.



Pliant Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Pliant Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=14.20/0
=

Pliant Therapeutics's Share Price of today is $14.20.
Pliant Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Pliant Therapeutics  (NAS:PLRX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Pliant Therapeutics PS Ratio Related Terms

Thank you for viewing the detailed overview of Pliant Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pliant Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
260 Littlefield Avenue, South San Francisco, CA, USA, 94080
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Executives
Hans Hull officer: Chief Business Officer C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025
Eric Lefebvre officer: Chief Medical Officer C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Keith Lamont Cummings officer: Chief Financial Officer C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Bernard Coulie director, officer: President and CEO C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Mike Ouimette officer: General Counsel C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Thomas A Mccourt director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lily Cheung officer: Chief Human Resource Officer 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Katharine Knobil director C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Kevin P Starr 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Smital Shah director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Redmile Group, Llc 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129